Latest Biotech News

Merck has agreed to acquire Terns Pharmaceuticals for about $6.7 billion, securing TERN-701, an oral BCR::ABL tyrosine kinase inhibitor in phase 1/2 for Philadelphia chromosome-positive...

Gilead announced it will acquire Ouro Medicines for about $2.17 billion, adding the autoimmune-stage BCMAxCD3 T-cell engager gamgertamig (OM336). The front-loaded structure includes $1.675 billion...

The FDA approved Corcept Therapeutics’ Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal...

The FDA granted Denali Therapeutics accelerated approval for Avlayah (tividenofusp alfa), a Hunter syndrome gene therapy, in a decision that runs counter to recent rare-disease rejection patterns...

Innate Pharma discontinued its phase 1/2 NK cell engager program IPH6501, ending the B-cell non-Hodgkin lymphoma study as part of a strategic pipeline prioritization. Innate had been evaluating...

Beam Therapeutics reported positive proof-of-concept readouts for its base editing therapy BEAM-302 in alpha-1 antitrypsin deficiency, showing restored functional protein production and meaningful...

Maze Therapeutics said its phase 2 program for MZE829, an oral dual-mechanism APOL1 inhibitor, achieved a clinically meaningful mean reduction in urine protein levels in APOL1-mediated kidney...

Countable Labs secured CE marking for its Countable 4 single-molecule PCR platform, positioning the instrument for European biopharma and contract manufacturing customers. The company says its...

PhaseV debuted AI Conductor, an AI-driven clinical development offering aimed at automating trial execution tasks from protocol development through regulatory submission readiness. The platform is...

Researchers from Université Claude Bernard Lyon’s Institut des Sciences Analytiques reported a targeted proteomics workflow to improve host-cell protein (HCP) monitoring across variable...

Merck & Co. has agreed to buy Terns Pharmaceuticals for about $6.7 billion, securing Terns’ lead oral BCR::ABL1 tyrosine kinase inhibitor TERN-701 as it prepares for major patent expirations...

The FDA approved Denali Therapeutics’ Avlayah (tividenofusp alfa) for Hunter syndrome (mucopolysaccharidosis II) under the accelerated approval pathway, a notable win amid scrutiny that has...

The FDA approved Corcept Therapeutics’ Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal...

Beam Therapeutics reported updated proof-of-concept data for its base-editing therapy BEAM-302 in alpha-1 antitrypsin deficiency (AATD), saying treatment restored functional protein production and...

Maze Therapeutics disclosed positive mid-stage topline results for MZE829, an oral APOL1 inhibitor targeting a broad set of APOL1-mediated kidney diseases (AMKD), reporting a clinically meaningful...

Gilead Sciences agreed to acquire Ouro Medicines in a deal valued at about $2.17 billion, adding gamgertamig (OM336), a BCMAxCD3 T-cell engager, to its autoimmune pipeline. The transaction...

Countable Labs announced it has obtained CE marking for its Countable 4 platform, a single-molecule PCR instrument designed to detect rare variants with low variant allele frequencies and deliver...

Researchers at Université Claude Bernard Lyon’s Institut des Sciences Analytiques reported scout-triggered MRM (st-MRM), a targeted proteomics workflow designed to improve host-cell protein (HCP)...

PhaseV debuted an AI offering called AI Conductor to automate clinical development tasks, aiming to harmonize data across studies and make submissions “submission-ready from the start.” The...

ProteomEdge, a Sweden-based SciLifeLab and KTH spinout, secured SEK 8 million in a seed financing to expand its absolute quantitation workflow for mass spectrometry-based proteomics. The...